Experienced in Hypercalcemia

Jalid Sehouli

Charité Campus Virchow
Berlin, BE, DE 
Experienced in Hypercalcemia
Charité Campus Virchow
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Jalid Sehouli practices in Berlin, Germany. Mr. Sehouli is rated as an Experienced expert by MediFind in the treatment of Hypercalcemia. His top areas of expertise are Ovarian Cancer, Ascites, Vulvar Cancer, Lymphadenectomy, and Vulvectomy.

His clinical research consists of co-authoring 671 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hypercalcemia.

Gender
Male

Locations

Charité Campus Virchow
Berlin, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients
A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Ganetespib, Niraparib, Carboplatin, Paclitaxel, Gemcitabine
Study Phase: Phase 2
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: March 20, 2025
Intervention Type: Drug
Study Drug: Trabectidin
Study Phase: Phase 4
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 3
Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Enrollment Status: Active_not_recruiting
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drugs: Pazopanib, Gemcitabine
Study Phase: Phase 2
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Phase: Phase 2
Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes - LUDOC Study
Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes - LUDOC Study
Enrollment Status: Completed
Publish Date: February 25, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
View 8 Less Clinical Trials

671 Total Publications

Correction: Impact of HIV infection on cervical intraepithelial neoplasia detection in pregnant and non-pregnant women in Germany: a cross-sectional study.
Correction: Impact of HIV infection on cervical intraepithelial neoplasia detection in pregnant and non-pregnant women in Germany: a cross-sectional study.
Journal: Archives of gynecology and obstetrics
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sehouli's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 47 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile